AltruBio is a private, clinical-stage biotech focused on novel biologics that modulate T-cell activity via the PSGL-1 checkpoint. The company's pipeline is anchored by ALTB-268, a next-generation candidate for ulcerative colitis now in Phase 2a, with plans for indication expansion. Having recently secured a significant $225M Series B financing, AltruBio has strengthened its financial position to advance its clinical programs. The company operates with a dual headquarters in San Francisco and a key R&D center in Taipei, Taiwan.
PSGL-1:T-Cell Checkpoint Regulator Platform; develops biologics to modulate T-cell homeostasis by targeting the PSGL-1 pathway.
Funding History
5
Total raised:$801M
Series B$225MUndisclosed
Series B$225MBVF Partners
Series B$225MBVF Partners
Series A$63MBVF Partners
Opportunities
The large and growing market for autoimmune diseases like ulcerative colitis and psoriasis presents a significant commercial opportunity for a safe, durable therapy.
The platform's potential for expansion into multiple immunological indications could create a valuable pipeline from a single core technology.
Success in the niche, high-need area of acute Graft vs.
Host Disease could provide an early pathway to approval and revenue.
Risk Factors
The company faces high clinical risk, as its value depends entirely on the success of ALTB-268 in ongoing and future trials.
The autoimmune disease therapeutic landscape is intensely competitive, requiring clear differentiation from existing treatments.
Despite a recent large financing, the capital-intensive nature of drug development poses ongoing financial and operational execution risks.
Competitive Landscape
AltruBio competes in crowded autoimmune markets (e.g., UC, psoriasis) against major pharmaceutical companies with numerous approved biologics (anti-TNF, IL-12/23, JAK inhibitors). Its differentiation hinges on the novel PSGL-1 mechanism aiming for improved safety/durability. In aGvHD, the competition is less dense but includes newer agents like Jakafi (ruxolitinib) and other late-stage candidates.
